(Q36115924)

12 August 2017

Dose-response study of ibandronate in the treatment of cancer-associated hypercalcaemia (English)

1 reference

12 August 2017

S H Ralston

1

1 reference

12 August 2017

D Thiébaud

2

1 reference

12 August 2017

Z Herrmann

3

1 reference

12 August 2017

E U Steinhauer

4

1 reference

12 August 2017

B Thürlimann

5

1 reference

12 August 2017

J Walls

6

1 reference

12 August 2017

M R Lichinitser

7

1 reference

12 August 2017

R Rizzoll

8

1 reference

12 August 2017

H Hagberg

9

1 reference

12 August 2017

H J Huss

10

1 reference

12 August 2017

M Tubiana-Hulin

11

1 reference

12 August 2017

J J Body

12

1 reference

12 August 2017

language of work or name

English

0 references

publication date

1 January 1997

1 reference

British Journal of Cancer

12 August 2017

1 reference

12 August 2017

75

1 reference

12 August 2017

2

1 reference

12 August 2017

295-300

1 reference

Effective treatment of malignant hypercalcaemia with a single intravenous infusion of clodronate

12 August 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Single-dose intravenous therapy with pamidronate for the treatment of hypercalcemia of malignancy: comparison of 30-, 60-, and 90-mg dosages

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

The hypercalcemia of malignancy: pathogenesis and management

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Gallium nitrate inhibits calcium resorption from bone and is effective treatment for cancer-related hypercalcemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Mechanism of malignant hypercalcaemia in carcinoma of the breast

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Dose/response study of aminohydroxypropylidene bisphosphonate in tumor-associated hypercalcemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Effects of a synthetic peptide of a parathyroid hormone-related protein on calcium homeostasis, renal tubular calcium reabsorption, and bone metabolism in vivo and in vitro in rodents

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

The pathogenesis of humoral hypercalcaemia of malignancy

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Parathyroid hormone-related protein in hypercalcaemia of malignancy.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Cancer-associated hypercalcemia: morbidity and mortality. Clinical experience in 126 treated patients

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Medical management of hypercalcaemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Bone metastases and tumor-induced hypercalcemia

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Treatment of tumour-induced hypercalcaemia with the bisphosphonate pamidronate: dose-response relationship and influence of tumour type.

2 October 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Hypercalcemia in breast cancer. Reassessment of the mechanism.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Malignancy-associated hypercalcaemia: relationship between mechanisms of hypercalcaemia and response to antihypercalcaemic therapy.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Bone and renal components in hypercalcemia of malignancy and responses to a single infusion of clodronate.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Renal phosphate threshold and response to pamidronate in humoral hypercalcaemia of malignancy.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

Response to retreatment of malignant hypercalcemia with the bisphosphonate AHPrBP (APD): respective role of kidney and bone.

2 July 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2063262

A single-day treatment of tumor-induced hypercalcemia by intravenous amino-hydroxypropylidene bisphosphonate

2 July 2018

1 reference

12 December 2020

Comparison of three intravenous bisphosphonates in cancer-associated hypercalcaemia

1 reference

12 December 2020

Breast cancer-associated hypercalcaemia: a reassessment of renal calcium and phosphate handling

1 reference

12 December 2020

Parathyroid hormone-related protein: elevated levels in both humoral hypercalcemia of malignancy and hypercalcemia complicating metastatic breast cancer

1 reference

12 December 2020

BM 21.0955, a potent new bisphosphonate to inhibit bone resorption

1 reference

12 December 2020

Dose-response study of alendronate sodium for the treatment of cancer-associated hypercalcemia

1 reference

12 December 2020

Methylpentylaminopropylidenebisphosphonate (BM 21.0955): a new potent and safe bisphosphonate for the treatment of cancer-associated hypercalcemia

1 reference

12 December 2020

Comparative study of available medical therapy for hypercalcemia of malignancy

1 reference

12 December 2020

Identifiers

DOI

10.1038/BJC.1997.48

1 reference

12 August 2017

1 reference

12 August 2017

PubMed publication ID

9010041

1 reference